AdAlta Limited
AdAlta Limited
Your view on 1AD.AX
Overview
What the company does, where it operates, and who runs it.
About AdAlta Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Charles Oldham
- Headquarters
- 697 Burke Road, Camberwell, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Timothy Charles Oldham
- Headquarters
- 697 Burke Road, Camberwell, VIC, AU
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other related fibrotic diseases.
The company has forged strategic alliances, including a collaboration with GE Healthcare to identify i-bodies that bind to granzyme B, and a partnership with Carina Biotech Pty Ltd. focused on developing CAR-T cell products designed to target various solid tumor antigens.
AdAlta Limited was founded in 2006 and is headquartered in Bundoora, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for AdAlta Limited. Starting points for AdAlta Limited: beta 0.19 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for AdAlta Limited. AdAlta Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for AdAlta Limited. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterSep 2023 | Next quarterDec 2023 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | −AUD 0.02 |
| Lowest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | −AUD 0.02 |
| Highest estimate | AUD 0.00 | AUD 0.00 | −AUD 0.04 | −AUD 0.02 |
| Number of analysts | 0 | 0 | 1 | 1 |
| A year ago | — | — | −AUD 0.001 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterSep 2023 | Next quarterDec 2023 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 3.20M | AUD 3.20M | AUD 3.59M | AUD 1.73M |
| Lowest estimate | AUD 3.20M | AUD 3.20M | AUD 3.59M | AUD 1.73M |
| Highest estimate | AUD 3.20M | AUD 3.20M | AUD 3.59M | AUD 1.73M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | — | — | AUD 0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for AdAlta Limited. AdAlta Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACR.AXAcrux Limited | Healthcare | Biotechnology | — | ||
| ANR.AXAnatara Lifesciences Ltd | Healthcare | Biotechnology | — | ||
| BIT.AXBiotron Limited | Healthcare | Biotechnology | — | ||
| CTQ.AXCareteq Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| EXL.AXElixinol Wellness Limited | Healthcare | Drug Manufacturers - Specialty & Generic | — | ||
| IBX.AXImagion Biosystems Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| OAK.AXOakridge International Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| OSX.AXOsteopore Limited | Healthcare | Medical - Instruments & Supplies | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PHRRFPharmaTher Holdings Ltd. | Healthcare | OTC | $5.3M | ||
| PHVSPharvaris N.V. | Healthcare | NASDAQ | $2.2B | ||
| PHYOFIXICO plc | Healthcare | OTC | $6.5M | ||
| PKTXProtoKinetix, Incorporated | Healthcare | OTC | $2.7M | ||
| PLRXPliant Therapeutics, Inc. | Healthcare | NASDAQ | $41.0M | ||
| PLRZPolyrizon Ltd. | Healthcare | NASDAQ | $12.4M | ||
| PLURPluri Inc. | Healthcare | NASDAQ | $9.9M | ||
| PLXProtalix BioTherapeutics, Inc. | Healthcare | AMEX | $254.6M | ||
| PLYXPolaryx Therapeutics, Inc. Common Stock | Healthcare | NASDAQ | $80.3M | ||
| PMCBPharmaCyte Biotech, Inc. | Healthcare | NASDAQ | $3.0M | ||
| PMNProMIS Neurosciences, Inc. | Healthcare | NASDAQ | $28.2M | ||
| PMVPPMV Pharmaceuticals, Inc. | Healthcare | NASDAQ | $65.1M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of AdAlta Limited.